Does Medicaid cover GLP-1 medications?

It depends

The GLP-1 class splits along its indications: prescribed for type 2 diabetes, these drugs are coverable in every state through the Medicaid Drug Rebate Program (behind prior authorization and step therapy), while prescribed for weight loss they fall into a category federal law expressly lets states exclude — and only a minority of states have chosen to cover them for obesity.

Covered when The GLP-1 is prescribed for documented type 2 diabetes and the state's prior-authorization and step-therapy requirements are met — coverable in every state through the rebate program.
Covered when You're in a state that covers anti-obesity medications and you meet its criteria — typically BMI ≥30 (or ≥27 with a comorbidity), documented lifestyle attempts, and periodic proof of response.
Not when The drug is prescribed for weight loss in a state that exercises its 1927(d)(2) authority to exclude anti-obesity agents — the majority position among states.

Verified 2026-08-12Reviewed by Tom Kazarian, former VP at eHealth3 primary sourcesHow verdicts are made

What flips the answer

Covered when
The GLP-1 is prescribed for documented type 2 diabetes and the state's prior-authorization and step-therapy requirements are met — coverable in every state through the rebate program.
Covered when
You're in a state that covers anti-obesity medications and you meet its criteria — typically BMI ≥30 (or ≥27 with a comorbidity), documented lifestyle attempts, and periodic proof of response.
Covered when
The prescription rests on a non-obesity indication of a weight-loss brand — Wegovy for cardiovascular risk reduction, Zepbound for obstructive sleep apnea — which is a medically accepted indication with stronger coverage footing even in exclusion states.
Not covered when
The drug is prescribed for weight loss in a state that exercises its 1927(d)(2) authority to exclude anti-obesity agents — the majority position among states.
Not covered when
Step therapy isn't satisfied — the state wants metformin or its preferred GLP-1 tried first, and the chart doesn't document the trial or the reason to skip it.
Not covered when
A covered anti-obesity authorization lapses at reauthorization because the required weight-loss response wasn't documented — continuation criteria are as real as initial criteria in AOM-covering states.

Key facts

Verdict: It depends
Applies to: GLP-1 · Medicaid
Covered when: The GLP-1 is prescribed for documented type 2 diabetes and the state's prior-authorization and step-therapy requirements are met — coverable in every state through the rebate program.
Not covered when: The drug is prescribed for weight loss in a state that exercises its 1927(d)(2) authority to exclude anti-obesity agents — the majority position among states.
Varies by state: Yes
Verified: 2026-08-12 · 3 primary sources

One legal frame explains the whole GLP-1 landscape. Under Section 1927 of the Social Security Act, manufacturers that sign the national rebate agreement get their covered outpatient drugs covered by every state Medicaid program for medically accepted indications — and Novo Nordisk and Eli Lilly, makers of the semaglutide family (Ozempic, Wegovy, Rybelsus) and the tirzepatide family (Mounjaro, Zepbound), participate. But the same statute, at 1927(d)(2), lists categories a state may exclude or restrict, and 'agents when used for weight loss' is on that list. The result: the identical molecule is a must-cover drug when treating diabetes and an optional one when treating obesity, and states have answered the optional question differently.

The diabetes lane is the settled one. GLP-1s prescribed for type 2 diabetes — Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza — are coverable in all fifty states, managed through preferred drug lists and utilization controls rather than exclusions: prior authorization documenting the diagnosis, step therapy through metformin or the state's preferred GLP-1, quantity limits tracking approved dosing, and periodic reauthorization. A state's PDL usually prefers one or two agents in the class, so which GLP-1 fills without a fight varies even where all are technically covered.

The weight-loss lane is the live policy battleground. Wegovy, Zepbound, and Saxenda carry weight-management indications, and covering them for obesity is a state choice — one that roughly a dozen-plus states had made as of recent counts, with the list shifting in both directions as budget pressure from GLP-1 spending collides with obesity-treatment advocacy (states have both added and dropped anti-obesity coverage in recent cycles). Where coverage exists, expect the strictest criteria in the pharmacy program: BMI thresholds (commonly ≥30, or ≥27 with comorbidities), documented lifestyle-intervention attempts, sometimes participation in a weight-management program, and reauthorization contingent on demonstrated weight loss.

The line between the lanes is blurring at the edges, which is worth knowing before accepting a denial. Newer FDA approvals give some 'weight-loss' brands non-obesity indications — Wegovy for cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight, Zepbound for obstructive sleep apnea — and a prescription grounded in one of those indications is a medically accepted indication of a rebate-program drug, not a bare weight-loss use, so it stands on stronger coverage footing even in states that exclude anti-obesity drugs as a class. States are still working out how they handle these hybrid cases in prior-authorization criteria, so the current PDL document and denial-letter reasoning matter more here than anywhere else in the class.

Varies by state

Diabetes-indication coverage exists everywhere but differs in preferred agents, step order, and PA criteria. Weight-loss coverage is the true state split: a minority of states cover anti-obesity GLP-1s (with BMI thresholds and reauthorization rules that differ), most exclude them, and policies have been actively changing year to year. How states treat the newer cardiovascular and sleep-apnea indications also varies.

What people typically pay

With coverage

An approved GLP-1 costs a Medicaid member at most a nominal copay — typically $0–$8 per fill depending on the state's pharmacy copay schedule.

Without coverage

List prices run roughly $1,000–$1,350 per month across the class; manufacturer self-pay programs have brought some agents to about $350–$650 per month, still $4,000–$8,000 a year for an ongoing therapy.

Because these are maintenance drugs, the annual out-of-pocket delta is enormous — which is why nailing the correct covered indication and completing prior authorization beats cash pay for anyone who plausibly qualifies.

How to actually get it covered

Anchor the indication first: which condition is this prescription actually treating? Diabetes, obesity, cardiovascular risk, or sleep apnea lead to different coverage answers, and the diagnosis code on the prior authorization is the single most consequential line in the file.
Check the state PDL (or managed-care formulary) for the class: it shows which GLP-1s are preferred, whether anti-obesity agents are covered at all, and the written PA criteria — your prescriber's office can pull this, or the state Medicaid pharmacy page publishes it.
Have the prescriber submit a complete prior authorization: diagnosis with supporting labs (A1C for diabetes, BMI and comorbidities for obesity), prior-treatment history satisfying step therapy, and the specific FDA indication being invoked.
If you're in an AOM-covering state, treat continuation as part of the plan from day one: calendar the reauthorization date and make sure follow-up visits record weight response, because approvals are conditional on documented benefit.
If denied, match the appeal to the denial type: a step-therapy or documentation denial is cured with records; a category denial ('weight-loss drugs excluded') is only beatable by re-grounding the request on a covered indication the patient genuinely has — or it isn't beatable, and the honest fallback is manufacturer cash-pay programs.

Common questions

Which GLP-1 drugs will Medicaid actually pay for?

For type 2 diabetes: the diabetes-branded agents — Ozempic, Rybelsus, Mounjaro, Trulicity, Victoza — are coverable in every state, though your state's preferred drug list decides which fills without extra steps and which requires trying the preferred agent first. For weight loss: Wegovy, Zepbound, or Saxenda only in the minority of states that cover anti-obesity medications, under strict BMI and documentation criteria. The state PDL, not the drug's fame, determines what the pharmacy can dispense.

Why does Medicaid cover the same drug for diabetes but not for weight loss?

Because federal law treats the uses differently. The rebate statute obligates states to cover participating manufacturers' drugs for medically accepted indications, but section 1927(d)(2) explicitly permits states to exclude or restrict 'agents when used for weight loss' — a carve-out written decades before GLP-1s existed. Diabetes use sits inside the mandatory zone; obesity use sits inside the optional one, and most states, facing GLP-1 budget exposure in the billions, have declined the option or attached strict criteria to it.

Is my state one of the ones that covers GLP-1s for weight loss?

The list is genuinely unstable — roughly a dozen-plus states have covered anti-obesity medications in recent years, but states have both joined and left the list as costs mounted, so any static list ages fast. The authoritative check takes minutes: search your state Medicaid pharmacy program's preferred drug list for Wegovy or Zepbound, or call the pharmacy line on your member card. If covered, the PA criteria (BMI, comorbidities, lifestyle documentation, reauthorization rules) will be published alongside.

Can I get Wegovy or Zepbound covered through their heart or sleep-apnea indications instead?

Sometimes, and it's the most consequential recent development in this class. Wegovy is FDA-approved to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight; Zepbound is approved for moderate-to-severe obstructive sleep apnea with obesity. A prescription documented on those indications — cardiology notes, a sleep study — invokes a medically accepted indication rather than bare weight-loss use, which weakens a category exclusion's application. States differ in how their criteria handle it, so expect prior authorization and be precise about the qualifying diagnosis.

That's the general answer. Yours is written in your actual policy.

Drop in your policy or benefits document and get the answer for your exact coverage — with the clause it comes from. Nothing is stored.

Check my policy →